ArticleJournal for immunotherapy of cancer2023

First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors.

Rom Leidner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.